Now I have all the information I need. Let me write the final consolidated review.

---

## Summary

This paper introduces HS (Hypothesis-based and Structure-based) prompting, which combines MECE-structured problem decomposition with hypothesis generation, prioritization, and active information-seeking to help LLMs solve many-to-one diagnostic problems in business consulting and medical diagnosis. The method is evaluated on 3 business cases and 4 medical cases with domain expert evaluation (5 consultants, 5 doctors), alongside qualitative analysis and an ablation study on "Q prompting" (adding one sentence encouraging information requests). While the qualitative insights are genuinely informative, the quantitative evaluation suffers from a trial-selection procedure that compromises its evidentiary value.

## Strengths

- **Qualitative evidence provides concrete, detailed insight into why HS differs from baselines**: The case narratives (Section 4.1, line 95; Section 4.2, line 122) show HS exploring problems more systematically — in medical Case 3, HS broke down possibilities into six causes (three urgent, three non-urgent) while CoTQ identified only two; in business Case 2, HS partitioned the problem into revenue and cost and drilled into variable costs while baselines scattered their inquiries without converging on root causes.

- **HS succeeds where baselines fail on the most challenging case**: On medical Case 4 (variant angina, an atypical and difficult diagnosis), HS was the only method to reach the correct diagnosis, adaptively shifting and revisiting hypotheses and requesting targeted tests (coronary angiography, provocation tests), while IO, IOQ, and CoTQ all stopped early with incorrect or overly broad diagnoses (Section 4.2, lines 118–122).

- **Ablation study isolates the "Q prompting" effect**: Adding the single sentence "You can request one data in each response if needed" is shown to improve performance by encouraging proactive information-seeking (Section 5, line 131). This is a clean, reproducible finding analogous to "Let's think step by step."

- **Domain expert evaluation with separation between criterion-setters and scorers**: The experts who defined the evaluation criteria did not participate in scoring (Section 4.1, line 81; Section 4.2, line 104), avoiding a common evaluation confound.

- **Honest documentation of failure modes**: The paper transparently reports that HS underperformed on business Case 1 (Section 4.1, line 91), that all methods failed on medical Case 5 (Section 5, line 129), and that HS's single-hypothesis orientation may misalign with real-world clinical practice (Section 4.2, line 120). This candor increases credibility.

## Weaknesses

### Fatal
None.

### Major

- **Trial selection procedure renders the quantitative results unreliable for comparative claims**: For the medical evaluation (Section 4.2, line 110), "a single physician reviewed them and selected the best trial from the three trials" — only the best of three runs per method was retained. For the business evaluation (Section 4.1, line 83), "two consultants selected both the best and the worst trials for each method" from 36 trials, yielding a non-random hand-curated subset of 24. In both domains the reported scores (medians, quartiles, averages) are computed over selectively curated outputs, not the full sampling distribution of each method. Since stochastic methods can vary across runs, selecting best/worst runs can differentially inflate or deflate methods with higher variance. The authors acknowledge the medical results "might not be statistically significant" (line 116) yet present the business results without this caveat despite the same selection issue. These numbers cannot reliably support superiority claims.

- **Very small case set with limited statistical rigor**: The evaluation rests on only 3 business cases and 4 medical cases. No significance tests, confidence intervals beyond basic quartiles, or effect-size measures are reported for the business domain. No inter-rater reliability statistic (e.g., Fleiss' kappa or ICC) is reported for either domain despite 5 evaluators per domain providing subjective scores. With this thin quantitative base, the paper's comparative claims are not empirically well-supported.

### Minor

- **No prompt templates provided, limiting reproducibility**: The paper describes the HS method via a 5-step conceptual guide (Section 3) but does not include the actual prompt templates used for HS or any baseline (IO, IOQ, CoTQ). The claimed "easy-to-follow guide for crafting examples" is presented only as high-level prose. For a prompting paper, the exact prompts are the primary artifact; their absence makes independent reproduction and adaptation unnecessarily difficult.

- **Evaluation limited to a single model (GPT-4 via chat interface)**: Tested on only one LLM, leaving open whether the benefits of HS generalize. The paper acknowledges this limitation (Section 6, line 142), but it remains a narrow empirical base.

### Trivial
None.

## Nice-to-Haves

- Including a structurally simpler baseline (e.g., prompting the LLM to "break the problem into MECE categories and generate hypotheses" without the full 5-step HS structure) would help isolate which component of HS drives improvements.
- Reporting inter-rater reliability statistics would increase confidence in the subjective expert scores.
- Reporting the results of *all* trials (even if only evaluated by a cheaper automated metric) would address the trial-selection concern.

## Removed Points

These points were flagged in the input reviews but are removed or downgraded after verification:

- *"Weak baselines / exclusion of ToT and GoT"* — **Removed**. The paper provides a reasonable justification (Section 4, line 72): the interactive, non-repetitive nature of diagnosis tasks makes external-search methods like ToT/GoT difficult to apply. This is a legitimate constraint, not a flaw.
- *"Missing related works (decomposed prompting, self-ask)"* — **Removed** per review guidelines (cannot verify from paper alone).
- *"Business cases all focus on declining profitability"* — **Removed**. The paper explicitly scopes this choice (Section 4.1, line 79).
- *"Case 5 exclusion from medical results"* — **Removed**. The paper addresses this directly (Section 5, line 129).
- *"Method underspecified as fatal reproducibility issue"* — **Downgraded to Minor**. The conceptual 5-step method is described; the lack of exact prompts is real but does not invalidate the paper's contribution.
- *"Formatting/style/typo criticisms"* — **Removed** per guidelines (parser artifacts, not author errors).

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Report all trials, not selected subsets.** Present the full distribution of scores across all runs per method per case, or use a two-stage evaluation (cheap automated metric on all trials, expert evaluation on a random subset) to demonstrate that trial selection does not bias the comparison.
2. **Run more trials per method** (at least 5–10) to obtain reliable performance estimates.
3. **Release the exact prompt templates** for HS and all baselines as supplementary material — this is the single highest-leverage improvement for scientific value and reproducibility.
4. **Include at least one structurally similar baseline** (e.g., simple MECE decomposition prompting without the full iterative HS structure) to isolate the contribution of each component.
5. **Report inter-rater reliability** for the subjective expert scores.

## Score and Decision

Score: 5.0  
Decision: Reject

MY FINAL SCORE: <score>5.0</score>
MY FINAL DECISION: <decision>Reject</decision>